129951-46-8

Basic information

• Product Name: 4,5-difluoro-2-nitrobenzoyl chloride
• Synonyms: 4,5-difluoro-2-nitrobenzoyl chloride
• CAS NO: 129951-46-8
• Molecular Weight: 221.548
• Mol File: 129951-46-8.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 4,5-difluoro-2-nitrobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-difluoro-2-nitrobenzoyl chloride(129951-46-8)
• EPA Substance Registry System: 4,5-difluoro-2-nitrobenzoyl chloride(129951-46-8)

Safety Data

• Hazardous Substances Data: 129951-46-8(Hazardous Substances Data)

Upstream product

• 20372-63-8 4,5-difluoro-2-nitrobenzoic acid 
• 455-86-7 3,4-Difluorobenzoic acid 

Downstream Products

• 611199-31-6 ethyl 2-(4,5-difluoro-2-nitrobenzoyl)-3-oxobutanoate 
• 127451-97-2 ethyl 3,4-difluoro-2-nitrobenzoylacetate 
• 847861-64-7 4,5-difluoro-N,N-dimethyl-2-nitrobenzamide 
• 1197346-93-2 C₁₅H₁₂F₂N₂O₅ 
• 1197346-87-4 C₁₄H₁₁F₂N₃O₃ 
• 346687-24-9 ethyl 6,7-difluoro-2-phenyl-4-oxoquinoline-3-carboxylate 
• 383875-96-5 6,7-difluoro-2-phenyl-1-prenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid ethyl ester 
• 383875-98-7 6,7-difluoro-2-phenyl-1-prenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 

Relevant articles and documents

Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme

A series of novel benzamide derivatives was designed, synthesized, and their inhibitory activities against glycogen phosphorylase (GP) in the direction of glycogen synthesis by the release of phosphate from glucose-1-phosphate were evaluated. The structur

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

ESTER DERIVATIVE AND MEDICINAL USE THEREOF

A therapeutic agent for hyperlipidemia which has no side effects on the liver unlike conventional MTP inhibitors and has excellent MTP inhibitory activity. Also, provided is an ester compound represented by the general formula (1): or a pharmaceutically a